Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells.

Thumbnail
View/Open
Accepted version (1.780Mb)
ICR Author
Jones, Robin
Author
Goff, PH
Riolobos, L
LaFleur, BJ
Spraker, MB
Seo, YD
Smythe, KS
Campbell, JS
Pierce, RH
Zhang, Y
He, Q
Kim, EY
Schaub, SK
Kane, GM
Mantilla, JG
Chen, EY
Ricciotti, R
Thompson, MJ
Cranmer, LD
Wagner, MJ
Loggers, ET
Jones, RL
Murphy, E
Blumenschein, WM
McClanahan, TK
Earls, J
Flanagan, KC
LaFranzo, NA
Kim, TS
Pollack, SM
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
<h4>Purpose</h4>To characterize changes in the soft-tissue sarcoma (STS) tumor immune microenvironment induced by standard neoadjuvant therapy with the goal of informing neoadjuvant immunotherapy trial design.<h4>Experimental design</h4>Paired pre- and postneoadjuvant therapy specimens were retrospectively identified for 32 patients with STSs and analyzed by three modalities: multiplexed IHC, NanoString, and RNA sequencing with ImmunoPrism analysis.<h4>Results</h4>All 32 patients, representing a variety of STS histologic subtypes, received neoadjuvant radiotherapy and 21 (66%) received chemotherapy prior to radiotherapy. The most prevalent immune cells in the tumor before neoadjuvant therapy were myeloid cells (45% of all immune cells) and B cells (37%), with T (13%) and natural killer (NK) cells (5%) also present. Neoadjuvant therapy significantly increased the total immune cells infiltrating the tumors across all histologic subtypes for patients receiving neoadjuvant radiotherapy with or without chemotherapy. An increase in the percentage of monocytes and macrophages, particularly M2 macrophages, B cells, and CD4+ T cells was observed postneoadjuvant therapy. Upregulation of genes and cytokines associated with antigen presentation was also observed, and a favorable pathologic response (≥90% necrosis postneoadjuvant therapy) was associated with an increase in monocytic infiltrate. Upregulation of the T-cell checkpoint TIM3 and downregulation of OX40 were observed posttreatment.<h4>Conclusions</h4>Standard neoadjuvant therapy induces both immunostimulatory and immunosuppressive effects within a complex sarcoma microenvironment dominated by myeloid and B cells. This work informs ongoing efforts to incorporate immune checkpoint inhibitors and novel immunotherapies into the neoadjuvant setting for STSs.
URI
https://repository.icr.ac.uk/handle/internal/5098
DOI
https://doi.org/10.1158/1078-0432.ccr-21-4239
https://doi.org/10.1158/1078-0432.ccr-21-4239
 
Collections
  • Clinical Studies
Subject
Humans
Sarcoma
Soft Tissue Neoplasms
Prognosis
Neoadjuvant Therapy
Retrospective Studies
Immunity
Tumor Microenvironment
Research team
Sarcoma Clinical Trials (R Jones)
Language
eng
Date accepted
2022-02-01
Citation
Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 28 (8), pp. 1701 - 1711

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.